Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Differential Methylation Levels in CpGs of the BIN1 Gene in Individuals With Alzheimer Disease

Salcedo-Tacuma, David BSc, MSc*,†; Melgarejo, Jesús D. MD†,‡; Mahecha, Maria F. BSc, MSc*,†; Ortega-Rojas, Jenny BSc, MSc*,†; Arboleda-Bustos, Carlos E. BSc, MSc, PhD*,†; Pardo-Turriago, Rodrigo MD§; Arboleda, Humberto MD, MSc*,†

Alzheimer Disease & Associated Disorders: October–December 2019 - Volume 33 - Issue 4 - p 321–326
doi: 10.1097/WAD.0000000000000329
Original Articles

Introduction: Late-onset Alzheimer disease (LOAD) is the most common dementia worldwide. APOE-[Latin Small Letter Open E]4 and BIN1 (Bridging Integrator 1) have been implicated in the pathogenesis of this disease, but, although DNA methylation of dinucleotide CpGs in the BIN1 gene influences alterations, it has not been studied in Hispanics.

Objective: The objective of this study was to evaluate the BIN1 3′ intergenic region DNA methylation patterns in a Colombian sample of LOAD patients.

Methods: A case-control study was conducted in 50 individuals with LOAD and 50 age-sex matched controls to determine associations of LOAD with DNA methylation. DNA was isolated from peripheral blood, and methylation levels of 8 CpGs were estimated by bisulfite conversion followed by Sanger sequencing with direct PCR analysis. Logistic regression models adjusted by age, sex, and APOE were used to calculate risk associations between methylation levels and LOAD.

Results: Overall, participants with LOAD had significantly lower methylation levels on CpG26 (0.86±0.11 vs. 0.95±0.05; P>0.001), CpG44 (0.84±0.09 vs. 0.94±0.06; P=0.001), and CpG87 (0.64±0.12 vs. 0.82±0.10; P>0.001). Adjusted regression models showed that decreased methylation levels of these CpGs remained as risk factors for LOAD (P<0.05).

Conclusions: Hypomethylation of CpGs in BIN1 might play an important role in the expression of BIN1 and may be a biomarker for identifying individuals at high risk of developing LOAD.

*Neurosciences Research Group, Faculty of Medicine

§Department of Neurology, Faculty of Medicine

Genetics Institute, Universidad Nacional de Colombia, Bogotá, Colombia

Laboratory of Neuroscience, University of Zulia, Maracaibo, Venezuela

Supported by COLCIENCIAS (code: 110171250010).

The authors declare no conflicts of interest.

Reprints: David Salcedo-Tacuma, BSc, MSc, Genetics Research Institute, office 202, School of Medicine, National University of Colombia, Cra 30-45 Campus universitario, Bogotá, 111321, Colombia (e-mail:

Received January 26, 2019

Accepted May 17, 2019

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved